• Esprinet reaffirmed its 2026 adjusted EBITDA guidance of EUR 77 million to EUR 82 million.
• Nine-month adjusted EBITDA rose 31% to EUR 49 million, with its margin widening to 1.53% from 1.29%.
• Gross sales increased 11% to EUR 3.5 billion, outpacing the market.
• Net financial debt reached EUR 417.8 million at September 30, reflecting volume growth, higher inventories and longer collection times.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esprinet S.p.A. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.